The US Food and Drug Administration recently updated its guidelines for dispensing mifepristone (the “abortion pill”) to now include certified pharmacies.
Mifepristone (Mifeprex), in a regimen with misoprostol, have been approved by the US Food and Drug Administration (FDA) to be dispensed to pharmacies for consumer use.
Mifepristone, also known as RU-486, is a medication used to terminate a pregnancy. The combination is 97% effective during the first 63 days of pregnancy. Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, and cause an abortion.
Both Mifeprex and the generic mifepristone tablets (200 mg), are available under the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, which produces the requirements that must be adhered to for medical termination of a pregnancy through 10 weeks. Under this program, mifepristone may be dispensed in person or by mail.
The FDA originally approved Mifeprex in 2000 and in 2019 approved the generic version, at which time the agency also approved a single shared REMS system for all mifepristone products. Until recently, the drug could only be dispensed by a few mail-order pharmacies or certified doctors and clinics. Under the current program:
--Mifepristone must be prescribed by a health care provider and is certified in the Mifepristone REMS Program.
--A patient agreement form must be reviewed with and signed by the patient and the health care provider with the risks of the mifepristone treatment being fully explained to the patient.
--The patient must be provided with a copy of the Patient Agreement Form and mifepristone Medication Guide.
--Mifepristone can only be dispensed under the supervision of a certified prescriber or by a certified pharmacy.
The FDA did not issue an announcement but instead updated its website to reflect the decision, as well as adding a series of questions and answers. The 2 manufacturers of the pill, Danco Laboratories and GenBioPro released statements saying the agency had informed them of their action.
Reference
Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation. US Food and Drug Administration. January 3, 2023. Accessed January 5, 2023. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More